Tumors derived from antigen presenting cells

Hyam I. Levitsky

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Vaccine strategies aimed at enhancing the processing of tumor antigens by activated 'professional' antigen presenting cells (APCs) can sometimes result in the generation of systemic T-cell mediated anti-tumor immune responses capable of eradicating a micrometastatic tumor burden. This observation raises the interesting question of why certain tumors such as B-cell lymphomas or myeloid leukemias malignancies in lineages normally characterized by potent APC capacity - fail to be eliminated by host T-cell responses. Potentially unique aspects of the immune response to such hematopoietic cancers are discussed in the context of the current understanding of factors regulating T-cell activation and tolerance. These considerations may have relevance for the application of cancer immunotherapy to this class of diseases.

Original languageEnglish (US)
Pages (from-to)281-287
Number of pages7
JournalSeminars in Immunology
Issue number5
StatePublished - Oct 1996


  • Antigen presenting cell
  • Antigen processing
  • Hematologic malignancies
  • Lymphoma
  • Tolerance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases
  • Immunology


Dive into the research topics of 'Tumors derived from antigen presenting cells'. Together they form a unique fingerprint.

Cite this